Magnesium
Active ingredient
Sold as Passiflora Plex
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Sublingual
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 34,471
Overview
Plain-language summary, compiled from the cited regulatory records
Magnesium is an ingredient used for the temporary relief of symptoms associated with irregular sleep patterns and ordinary restlessness [1]. It is not assigned to a specific drug class in the provided data [1].
This ingredient is available under various brand names, including Passiflora Plex [1]. In the past 12 months, there have been 34,471 adverse event reports associated with magnesium-containing products [2]. The most frequently reported adverse events include nausea, diarrhea, fatigue, off-label use, and the perception that the drug is ineffective [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 15, 2026 |
| US United States | FDA | 1 | July 15, 2021 |
GBUnited Kingdom· MHRA
4 products
Uses
Treatment of magnesium deficiency where the oral route of administration may be inappropriate, which may be due to malabsorption syndromes, chronic alcoholism, malnutrition, severe diarrhoea or patients on total parenteral nutrition.
How to take
USUnited States· FDA
1 product
Uses
Uses For the temporary relief of symptoms associated with irregular sleep patterns ordinary restlessness Directions To be taken ten minutes away from food. Invert bottle and shake lightly allowing drops to fall directly under the tongue or into ¼ oz of water.
Hold contents for about 20 seconds and swallow. To promote drop flow, invert bottle and shake before each use. Dosage frequency may be increased up to six times daily depending on the severity of symptoms. Adults and adolescents (12 years and older) Take 10 drops three times daily or as recommended by your healthcare practitioner.
Children (under 12 years) Take under the direction of your healthcare practitioner.
How to take
Sources & citations
- [1]MHRA (UK) · PL351040009 · revised May 15, 2026
- [2]FDA DailyMed · 0eabdf34-4d4c-32… · revised July 15, 2021 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.